What Recent Shake-ups Mean for Science
Imagine setting sail on a vast ocean of scientific uncertainty, where every wave brings a new medical challenge and every current pulls researchers in different directions.
For decades, National Institutes of Health (NIH) advisory committees have served as the compass and navigational charts guiding this voyage—steering everything from groundbreaking gene therapy trials to the development of COVID-19 vaccines. These committees of scientific experts provide independent guidance beyond federal employees, helping determine which research gets funded, what ethical boundaries should be established, and how public health priorities are set.
Steering biomedical research priorities
Ensuring ethical and safe research practices
Independent scientific advice
The renewal of the ACD charter in July 2025 initially appeared routine. However, the seemingly administrative move came with an unprecedented twist: all ten current members were relieved of service regardless of their term status 1 .
100% of ACD members replacedNearly four dozen committees across the Department of Health and Human Services have been terminated since January 2025, according to federal databases 2 .
~65% reduction in advisory committeesDelays in advisory council appointments could potentially stall the awarding of research grants throughout the biomedical science ecosystem 1 .
A storied panel that, since the mid-1970s, oversaw the rollout of synthetic insulin and the early days of gene therapy 2 .
The Novel and Exceptional Technology and Research Advisory Committee continued the work of the RAC, handling newer biosafety and ethical challenges like CRISPR gene drives 2 .
Members received emails from NIH Director Jay Bhattacharya notifying them that the committee was being "sunset" as part of efficiency measures 2 .
The committee presented its final "road map" to increase community engagement in NIH-funded science, praised by Bhattacharya for addressing rebuilding public trust 2 .
While many committees have been eliminated or reshuffled, the restructuring of the Advisory Committee on Immunization Practices (ACIP) reveals a different pattern. In September 2025, HHS and CDC announced the appointment of five new members to this critical committee that guides the nation's vaccination policies 3 .
Expertise: Epidemiology of infectious diseases, particularly tuberculosis
Position: Professor, Department of Population & Quantitative Health, Case Western Reserve University
Expertise: Maternal morbidity and mortality reduction; robotic-assisted surgery
Position: Obstetrician and Gynecologist, Baton Rouge General Hospital
Expertise: Pharmacy practice, medication access for underserved populations
Position: Director of Medication Access and Affordability, AscensionRx
Expertise: Pediatric cardiology; international medical missions
Position: Medical Director, For Hearts and Souls Free Medical Clinic
The changes to NIH advisory committees don't occur in a vacuum—they reflect a broader philosophical shift in the approach to scientific governance. A reform proposal from the Manhattan Institute outlines what it calls the SITE principles, intended to guide the transformation of NIH :
| Proposed Reform | Rationale | Implementation Status |
|---|---|---|
| Rescind "Notice of NIH's Interest in Diversity" | Replace "demographic diversity" focus with SITE principles | Implemented |
| Dismantle or reform SGMRO | Concerns about promotion rather than examination of "gender-affirming care" | Partial |
| Replace "ideologically loaded language" | Remove concepts like "sex assigned at birth" from NIH communications | Pending |
| End diversity statements | Protect "freedom of conscience" and avoid ideological litmus tests | Implemented |
The sudden dismissal of all ACD members—regardless of their term status—represents a significant loss of institutional knowledge at the highest level of NIH advisory structure 1 .
Similarly, the termination of NExTRAC eliminates a forum that had developed specialized expertise in the ethical dimensions of emerging biotechnologies.
The additional screening of individuals nominated to serve on Advisory Councils raises practical concerns about the timely review and awarding of grants 1 .
These committees serve as the second stage of NIH's peer review process, meaning delays in appointments could potentially slow down the entire biomedical research funding pipeline.
How will the loss of specialized committees affect oversight of emerging biotechnologies?
Will new screening processes streamline operations or create bottlenecks?
How will emphasis on different expertise affect NIH-funded research?